An essential component of the translation of the new knowledge generated by the CRE REDUCE will be to test the clinical safety and tolerability of the novel doses that aim to suppress the emergence of resistance.

Previous in vitro studies that have attempted to quantify the relationship between pharmacokinetics and pharmacodynamics and the development of resistance have mostly found that higher antimicrobial exposures are required. Since higher drug exposures lead to concerns for patient safety this multi-centre study will use therapeutic drug monitoring or TDM to optimize antimicrobial exposures and test for the safety and tolerability of the new doses.

Relevant Publications

Wong, Gloria, Briscoe, Scott, McWhinney, Brett, Ally, Mumtaz, Ungerer, Jacobus, Lipman, Jeffrey and Roberts, Jason A (2018) Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. Journal of Antimicrobial Chemotherapy, . doi:10.1093/jac/dky314

Heil, Emily L., Nicolau, David P., Farkas, Andras, Roberts, Jason A. and Thom, Kerri A. (2018) Pharmacodynamic target attainment for cefepime, meropenem and piperacillin/tazobactam using a pharmacokinetic/pharmacodynamic-based dosing calculator in critically ill patients. Antimicrobial Agents and Chemotherapy, . doi:10.1128/AAC.01008-18

Abdul-Aziz, Mohd H., Driver, Elicia, Lipman, Jeffrey and Roberts, Jason A. (2018) New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimisation rapid microbiological methods. Expert Opinion on Drug Metabolism and Toxicology, 14 7: 1-16. doi:10.1080/17425255.2018.1484452

Minichmayr, Iris K., Roberts, Jason A., Frey, Otto R., Roehr, Anka C., Kloft, Charlotte and Brinkmann, Alexander (2018) Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. The Journal of Antimicrobial Chemotherapy, 73 5: 1330-1339. doi:10.1093/jac/dkx526

 

Project members

Dr Menino Cotta

Dr Menino Cotta

UQ Development Fellow, School of Pharmacy, Faculty of Health and Behavioural Sciences
Jason Roberts

Professor Jason Roberts

Director
CRE RESPOND
Acting Director
UQ Centre for Clinical Research
NHMRC Leadership Fellow
The University of Queensland
Pharmacist Consultant
Royal Brisbane & Women’s Hospital

Associate Professor Sandra Peake

Dissemination Strategy Co-Lead
CRE RESPOND
ICU Physician and Chair of ANSICS-CTG Committee

Professor Jeffrey Lipman

Critical Care Research, Translation and Training Lead
CRE RESPOND
Emeritus Professor
UQ Centre for Clinical Research

Professor Gavin Joynt

Health Practitioner and Undergraduate Training Lead
CRE RESPOND
Critical Care Physician
Prince of Wales Hospital, Hong Kong